Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →ML Fraud Detection Score: Very High
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
19,864
Total Claims
$1.4M
Drug Cost
536
Beneficiaries
$2,654
Cost/Patient
Risk Score Breakdown 26/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-31%
Opioid rate vs peers
1.6% vs 2.2% avg
+88%
Cost per patient vs peers
$2,654 vs $1,411 avg
+33%
Brand preference vs peers
14.2% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Our machine learning model — trained on 281 confirmed fraud cases — gives this provider a "Very High" fraud-pattern score. All 20 decision trees in our ensemble model agree that this provider's prescribing patterns resemble those of confirmed fraud cases. This is a statistical finding, not an accusation.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
1.6%
Opioid Rate
309
Opioid Claims
$5,307
Opioid Cost
4.5%
Long-Acting Rate
Brand vs Generic
Brand: 2,805 claims · $964K
Generic: 16,985 claims · $452K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 707 | $218K |
| Dulaglutide | 93 | $56K |
| Raltegravir Potassium | 22 | $46K |
| Sitagliptin Phosphate | 124 | $40K |
| Empagliflozin | 108 | $36K |
| Linagliptin | 88 | $30K |
| Emtricitabine/Tenofov Alafenam | 12 | $29K |
| Rivaroxaban | 95 | $28K |
| Linaclotide | 41 | $22K |
| Fluticasone/Vilanterol | 38 | $19K |
| Atorvastatin Calcium | 1,386 | $19K |
| Dextromethorphan Hbr/Quinidine | 22 | $16K |
| Sacubitril/Valsartan | 42 | $16K |
| Insulin Aspart | 49 | $16K |
| Umeclidinium Bromide | 42 | $15K |
Prescribing Profile
Patient Profile
70
Avg Age
46%
Female
3.17
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data